Fluoride

Fluoride

SCHEMBL498862

F.Oc1nc(O)nc(O)n1

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24459 0.94
SCHEMBL4778229 0.89
Ammonia Solution, Strong SCHEMBL9538468 0.89 ALDH1A1 (0.31)
SCHEMBL4777357 0.89
Hydrochloric Acid SCHEMBL237157 0.89
Hydrochloric Acid SCHEMBL546609 0.89
Ammonia Solution, Strong SCHEMBL1138722 0.89 ALDH1A1 (0.31)
Bromide SCHEMBL7178493 0.89
SCHEMBL21385109 0.89
Hydrazine SCHEMBL3475792 0.84

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-10219129-A None JP disclosed
WO-2023200364-A1 METHODS FOR PRODUCING (1R,2S,5S)-N-[(1S)-1-CYANO-2-[(3S)-2-OXOPYRROLIDIN-3-YL]ETHYL]-3-[(2S)-3,3-DIMETHYL-2-[(2,2,2-TRIFLUOROACETYL)AMINO]BUTANOYL]-6,6-DIMETHYL-3-AZABICYCLO[3.1.0]HEXANE-2-CARBOXAMIDE ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "ПРОМОМЕД РУС" 2023-10-19 WO disclosed
US-9415088-B2 Use of AGR3 for treating cancer THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2016-08-16 US disclosed
US-20160051671-A1 COMBINATION OF BLyS INHIBITION AND ANTI-CD 20 AGENTS FOR TREATMENT OF AUTOIMMUNE DISEASE ARES TRADING S.A. (CH) 2016-02-25 US disclosed
EP-2233149-B1 Combination of transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) and anti-CD20 agents for treatment of autoimmune disease ZYMOGENETICS INC (US) 2016-02-10 EP disclosed
EP-1631313-B1 COMBINATION THERAPY FOR B CELL DISORDERS GENENTECH INC (US) 2015-03-11 EP disclosed
EP-2272868-B1 Combination therapy for B cell disorders GENENTECH INC (US) 2015-03-04 EP disclosed
US-8956611-B2 Combination of BLyS inhibition and anti-CD 20 agents for treatment of autoimmune disease ZYMOGENETICS, INC. (US) 2015-02-17 US disclosed
US-20140377257-A1 COMBINATION THERAPY FOR B CELL DISORDERS GENENTECH, INC. (US) 2014-12-25 US disclosed
US-8852591-B2 Combination of BLyS and/or APRIL inhibition and immunosuppressants for treatment of autoimmune disease ZYMOGENETICS, INC. (US) 2014-10-07 US disclosed
EP-0229108-B1 SOLUBILIZATION OF PROTEINS FOR PHARMACEUTICAL COMPOSITIONS USING POLYMER CONJUGATION CETUS CORPORATION (US) 1990-12-27 EP disclosed
EP-0402378-A1 CONJUGATION OF POLYMER TO COLONY STIMULATING FACTOR-1. CETUS CORP (US) 1990-12-19 EP disclosed
US-4917888-A Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation CETUS CORPORATION (US) 1990-04-17 US disclosed
WO-1989006546-A1 CONJUGATION OF POLYMER TO COLONY STIMULATING FACTOR-1 CETUS CORPORATION (US) 1989-07-27 WO disclosed
US-4847325-A PROTEINS CETUS CORPORATION (US) 1989-07-11 US disclosed
US-4818769-A TREATING SHIPPING FEVER, USING THE POLYPEPTIDE BONDED POLYOXYETHYLENE GLYCOL CETUS CORPORATION (US) 1989-04-04 US disclosed
US-4766106-A Solubilization of proteins for pharmaceutical compositions using polymer conjugation CETUS CORPORATION (US) 1988-08-23 US disclosed
EP-0247860-A2 Tumor necrosis factor formulation and its preparation CETUS ONCOLOGY CORPORATION (US) 1987-12-02 EP disclosed
EP-0229108-A1 SOLUBILIZATION OF PROTEINS FOR PHARMACEUTICAL COMPOSITIONS USING POLYMER CONJUGATION. CETUS CORP (US) 1987-07-22 EP disclosed
WO-1987000056-A1 SOLUBILIZATION OF PROTEINS FOR PHARMACEUTICAL COMPOSITIONS USING POLYMER CONJUGATION CETUS CORPORATION (US) 1987-01-15 WO disclosed